Wells Fargo’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-17,910
| Closed | -$282K | – | 7671 |
|
|
2024
Q1 | $282K | Buy |
17,910
+2,328
| +15% | +$35.8K | ﹤0.01% | 4255 |
|
|
2023
Q4 | $251K | Sell |
15,582
-21,939
| -58% | -$280K | ﹤0.01% | 4322 |
|
|
2023
Q3 | $477K | Sell |
37,521
-22,082
| -37% | -$305K | ﹤0.01% | 3815 |
|
|
2023
Q2 | $839K | Buy |
59,603
+11,213
| +23% | +$160K | ﹤0.01% | 3587 |
|
|
2023
Q1 | $748K | Buy |
+48,390
| New | +$808K | ﹤0.01% | 3582 |
|
|
2022
Q4 | – | Sell |
-1,614
| Closed | -$30K | – | 7806 |
|
|
2022
Q3 | $30K | Sell |
1,614
-763
| -32% | -$12K | ﹤0.01% | 5197 |
|
|
2022
Q2 | $31K | Sell |
2,377
-16,444
| -87% | -$181K | ﹤0.01% | 5260 |
|
|
2022
Q1 | $174K | Sell |
18,821
-11,486
| -38% | -$97.7K | ﹤0.01% | 5060 |
|
|
2021
Q4 | $296K | Sell |
30,307
-38,715
| -56% | -$728K | ﹤0.01% | 5045 |
|
|
2021
Q3 | $2.35M | Sell |
69,022
-147,092
| -68% | -$4.69M | ﹤0.01% | 3523 |
|
|
2021
Q2 | $7.91M | Sell |
216,114
-332,876
| -61% | -$12.9M | ﹤0.01% | 2431 |
|
|
2021
Q1 | $24.6M | Sell |
548,990
-153,397
| -22% | -$7.14M | 0.01% | 1509 |
|
|
2020
Q4 | $40.1M | Buy |
702,387
+185,093
| +36% | +$11M | 0.01% | 1110 |
|
|
2020
Q3 | $26.5M | Buy |
517,294
+19,058
| +4% | +$934K | 0.01% | 1226 |
|
|
2020
Q2 | $29.8M | Buy |
498,236
+32,810
| +7% | +$1.76M | 0.01% | 1124 |
|
|
2020
Q1 | $19.2M | Sell |
465,426
-17,182
| -4% | -$954K | 0.01% | 1252 |
|
|
2019
Q4 | $30M | Buy |
482,608
+34,481
| +8% | +$1.64M | 0.01% | 1212 |
|
|
2019
Q3 | $15.2M | Buy |
448,127
+383,004
| +588% | +$11.3M | ﹤0.01% | 1620 |
|
|
2019
Q2 | $1.47M | Buy |
65,123
+49,806
| +325% | +$1.17M | ﹤0.01% | 3593 |
|
|
2019
Q1 | $356K | Sell |
15,317
-12
| -0.1% | -$314 | ﹤0.01% | 4533 |
|
|
2018
Q4 | $322K | Buy |
15,329
+2,889
| +23% | +$71K | ﹤0.01% | 4623 |
|
|
2018
Q3 | $482K | Buy |
12,440
+8,107
| +187% | +$300K | ﹤0.01% | 4473 |
|
|
2018
Q2 | $171K | Sell |
4,333
-367
| -8% | -$10.8K | ﹤0.01% | 5117 |
|
|
2018
Q1 | $94K | Buy |
4,700
+3,483
| +286% | +$88.2K | ﹤0.01% | 5336 |
|
|
2017
Q4 | $28K | Sell |
1,217
-283
| -19% | -$5.54K | ﹤0.01% | 5707 |
|
|
2017
Q3 | $28K | Buy |
+1,500
| New | +$27.5K | ﹤0.01% | 5629 |
|
Other funds holding DCPH
Wells Fargo's DCPH Position: Q2 2024 in Review
Wells Fargo sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 17,910 shares — an estimated $282K sold.
Wells Fargo first reported a position in DCPH in Q3 2017 and held it in 26 quarters. The position peaked at $40.1M in Q4 2020. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- Wells Fargo reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Wells Fargo sold 17,910 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $282K.
- Wells Fargo first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 26 quarters.
- Wells Fargo's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $40.1M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.